Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01208467 · ClinicalTrials.gov registry record
Prognostic Biomarkers in Patients With Endometrial Cancer
A clinical trial of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma, sponsored by Gynecologic Oncology Group.
- Completed
- Registry status
- 2,824
- Enrollment target
- 1
- Study location
NCT01208467: Completed study of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma, sponsored by Gynecologic Oncology Group.
NCT01208467 is a study of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma that has completed, run by Gynecologic Oncology Group. The registered enrollment target is 2,824 participants, above the 123-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (2196% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01208467, a study of Endometrial Adenocarcinoma and Recurrent Uterine Corpus Carcinoma, has completed, sponsored by Gynecologic Oncology Group.
- COMPLETED
- Registry status
- 2,824 participants
- Enrollment target
- 1
- Study location
Study Summary
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
Primary Outcome
Parametric and non-parametric statistical tests will be performed to evaluate the association between ATR mutation status and demographic and clinical data. Product-limit estimates according to Kaplan-Meier method will be calculated and difference between survival according to ATR mutation status will be assessed using a two sided log rank test. The predictive ability of the final model will be assessed using a concordance index (C-statistic).
Conditions Studied
Interventions
- OTHER Laboratory Biomarker Analysis
Study Locations (1)
Pennsylvania
- Gynecologic Oncology Group - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,824 participants |
| Start Date | 2010-09 |
What the finished NCT01208467 record still lists
NCT01208467 is an observational study that tracks outcomes without assigning an intervention. Its 2,824 participants enrollment target places it among the larger protocols in the corpus, above the 123-participant average among 13 other Endometrial Adenocarcinoma trials with a reported enrollment target (2196% higher).
The record links to 6 conditions, with Endometrial Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Laboratory Biomarker Analysis is the first listed.
NCT01208467 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01208467 about?
NCT01208467 is a clinical study titled "Prognostic Biomarkers in Patients With Endometrial Cancer". This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
What is the current status of trial NCT01208467?
This trial is currently completed. The enrollment target is 2,824 participants. The study started on 2010-09.
What conditions does trial NCT01208467 study?
This clinical trial studies the following conditions: Endometrial Adenocarcinoma, Recurrent Uterine Corpus Carcinoma, Stage I Uterine Corpus Cancer, Stage II Uterine Corpus Cancer, Stage III Uterine Corpus Cancer.
What interventions are being tested in trial NCT01208467?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER).
Who is sponsoring clinical trial NCT01208467?
This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01208467 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Endometrial Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01208467's enrollment target sits among peer trials
2,824 1st of 13 higher than 13 of 13 other Endometrial Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Endometrial Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
RECRUITING · Phase 2
-
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
RECRUITING · Phase 2
-
A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
RECRUITING · Phase 1
-
Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
ACTIVE NOT RECRUITING · Phase 2
-
mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and Ovarian
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02273297 · 2,821 participants
Healthy Start: Exploring the Fuel-mediated Programming of Neonatal Growth
- NCT05932602 · 2,812 participants
AVEIR DR Coverage With Evidence Development (CED) Study
- NCT06150781 · 2,842 participants
Aimovig Pregnancy Exposure Registry
- NCT05443737 · 2,800 participants · Phase 3
Evaluation of a Telehealth Oncofertility Care Intervention in Adolescent and Young Adult Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia